Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021

10/27/2021 | 07:00am EST

Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=-N4HWcBprBQdgJyKg_3U4H_SJpqHdmyAjIVxwZeOCOuH4jSGrb01Oy0gr5ToZITycKsnrqFDz3PMv9YU_Q4HEA== BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the third quarter on Tuesday, November 9(th) , 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2021.

The slide presentation and audio of the webcast will be available via this https://www.globenewswire.com/Tracker?data=NilPeSSMQGp2rxYRZ4U5VY1Fz89dCAmKokmhaeh7eBgpXyx8haofV92DxdRMvLQxtyL0U4u4M6nG7LcAGHqW9Q4pu1yyxZAnghVV3QB8gBw= link.

To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:

 
United States international:          +1 646 741 3167 
 United States domestic (toll-free):   +1 877 870 9135 
 Germany:                              +49 (0) 692 2222 625 
 Conference ID:                        6835174 
 

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor Relations section of the Company's website at https://www.globenewswire.com/Tracker?data=LtKFmpO2Zm1xwLQ480qJCkMDXHcQzgHDDtSGRPU3pRklQ6xZYBk25zedathRIDB_MiuLVg7-Vt1GLhDPu724DQ== https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit https://www.globenewswire.com/Tracker?data=sR5QO5f3CubmBVlM5yaVgyFp53yDMUeuTNpfGLc9YMRuzvpv9lm46NCAkI01Ayeh7mUywQ2aHgdHMA79pyBccw== www.BioNTech.de.

BioNTech Contacts

Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

https://www.globenewswire.com/Tracker?data=cwZvsnaWKTH1isI4HmKBfVTJXVd3yWYxfasakVUa7TFy72iWbsajs4jv9RcJgfl4x2jQiAOilCSe4UkgIdHpZsE2oVhUjvbr96TTV8wSoFk= Investors@biontech.de

Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513

https://www.globenewswire.com/Tracker?data=iqIYR-gb1Jxp-JII4AywCDw5a99kqAUOAj3vh3YV-3D9-Py3IcEZdOLCQMKhkEQWUIWHI4d3YnpvPg72sTf0dbYHKgNMZeE5gnoxyS6YjH0= Media@biontech.de

(END) Dow Jones Newswires

October 27, 2021 07:00 ET (11:00 GMT)

All news about BIONTECH SE
05:58aFriday Equity Market Plunge Seen as Buying Opportunity to Wedbush as Cloud, Cybersecuri..
MT
04:45aCOVID-19 Vaccine Makers Working on Strategies Amid Omicron Variant
MT
02:48aBuying the Omicron dip
RE
11/28Currencies recover from Omicron chaos but analysts warn more volatility ahead
RE
11/28Currencies recover from Omicron chaos but analysts warn more volatility ahead
RE
11/28Asian Travel Stocks Fall on Omicron Fears
DJ
11/26Novavax developing vaccine that targets new COVID-19 variant
RE
11/26BIONTECH : will take two weeks to assess vaccine against latest Covid variant - Form 6-K
PU
11/26BIONTECH : Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY« in Children 5 ..
PU
11/26Novavax testing vaccine that targets new COVID-19 variant
RE
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 474 M 19 707 M 19 707 M
Net income 2021 9 220 M 10 398 M 10 398 M
Net cash 2021 9 793 M 11 045 M 11 045 M
P/E ratio 2021 8,37x
Yield 2021 -
Capitalization 74 268 M 84 049 M 83 760 M
EV / Sales 2021 3,69x
EV / Sales 2022 3,18x
Nbr of Employees 2 800
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 307,50 €
Average target price 259,68 €
Spread / Average Target -15,6%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE326.89%84 049
GILEAD SCIENCES, INC.20.61%88 146
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678
BEIGENE, LTD.34.56%32 622